GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChromaDex Corp (NAS:CDXC) » Definitions » Quick Ratio

ChromaDex (ChromaDex) Quick Ratio

: 1.70 (As of Dec. 2023)
View and export this data going back to 2008. Start your Free Trial

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. ChromaDex's quick ratio for the quarter that ended in Dec. 2023 was 1.70.

ChromaDex has a quick ratio of 1.70. It generally indicates good short-term financial strength.

The historical rank and industry rank for ChromaDex's Quick Ratio or its related term are showing as below:

CDXC' s Quick Ratio Range Over the Past 10 Years
Min: 0.87   Med: 1.58   Max: 6.35
Current: 1.7

During the past 13 years, ChromaDex's highest Quick Ratio was 6.35. The lowest was 0.87. And the median was 1.58.

CDXC's Quick Ratio is ranked worse than
68.77% of 1553 companies
in the Biotechnology industry
Industry Median: 3.56 vs CDXC: 1.70

ChromaDex Quick Ratio Historical Data

The historical data trend for ChromaDex's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChromaDex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.46 1.25 2.00 1.78 1.70

ChromaDex Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.78 1.88 1.81 1.78 1.70

Competitive Comparison

For the Biotechnology subindustry, ChromaDex's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ChromaDex Quick Ratio Distribution

For the Biotechnology industry and Healthcare sector, ChromaDex's Quick Ratio distribution charts can be found below:

* The bar in red indicates where ChromaDex's Quick Ratio falls into.



ChromaDex Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

ChromaDex's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(49.534-14.525)/20.622
=1.70

ChromaDex's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(49.534-14.525)/20.622
=1.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ChromaDex  (NAS:CDXC) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


ChromaDex Quick Ratio Related Terms

Thank you for viewing the detailed overview of ChromaDex's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ChromaDex (ChromaDex) Business Description

Traded in Other Exchanges
Address
10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segment namely Consumer Products, Ingredients segment and Analytical Reference Standards and Services. Majority of the revenue is earned from Consumer Products segment.
Executives
Brianna Gerber officer: SVP Finance / Interim CFO C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Champion River Ventures Ltd 10 percent owner C/O 7F, CHEUNG KONG CENTER, 2 QUEEN'S ROAD, CENTRAL K3 00000
Jaksch Frank L Jr director, 10 percent owner, officer: Chief Executive Officer 10005 MUIRLANDS BOULEVARD, SUITE G FIRST FLOOR, IRVINE CA 92618
Robert N Fried director 100 NORTH CRESCENT DRIVE, BEVERLY HILLS CA 90210
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Li Ka Shing 10 percent owner 79 DEEP WATER BAY ROAD, HONG KONG F4 00000
Chau Hoi Shuen Solina Holly 10 percent owner SUITES PT. 2909 & 2910, HARBOUR CENTRE, 25 HARBOUR ROAD, WANCHAI K3 999077
Hamed Shahbazi director C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Ann Cohen director C/O CHROMADEX CORPORATION, 10900 WILSHIRE BLVD. STE 600, LOS ANGELES CA 90024
Kristin Patrick director 3329 CAY DRIVE, SHERMAN OAKS CA 91423
Ng Wang Yu Gary director ROOM 1709 HARBOUR CENTER, 25 HARBOUR ROAD, WANCHAI K3 -
Caroline S Levy director 2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
Stephen A Block director INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 WEST 57TH ST, NEW YORK NY 10019
Lisa Hatton Harrington officer: General Counsel 53 SEA TERRACE, NEWPORT COAST CA 92657
Kevin M Farr officer: Chief Financial Officer MATTEL, INC., 333 CONTINENTAL BLVD, M1-1518, EL SEGUNDO CA 90245

ChromaDex (ChromaDex) Headlines

From GuruFocus

ChromaDex Named Brianna Gerber Chief Financial Officer

By Business Wire Business Wire 01-05-2023